Cathleen Chow

Can Higher-Dose Trulicity Pack a Stronger Punch than Currently Approved Doses?

Uncategorized /

Can Higher-Dose Trulicity Pack a Stronger Punch Than Currently Approved Doses? What the trial is testing: This study will test the effectiveness of different doses of Trulicity (dulaglutide), a GLP-1 agonist, in addition to metformin for type 2 diabetes. Trulicity is a once-weekly injectable treatment already FDA approved for type 2 diabetes. Its recommended dose […]

Can Higher-Dose Trulicity Pack a Stronger Punch than Currently Approved Doses? Read More »

GLP-1 Receptor Agonist Therapy with and without SGLT2 Inhibitors in Patients with Type 2 Diabetes

general /

Neves, MedicGLP Product J. S. et al. 2023) GLP-1 receptor agonist therapy with and without SGLT2 inhibitors in patients with type 2 diabetes. Journal of the American College of Cardiology, 82(6), pp. Full text not currently available from Enlighten. Background: Sodium-glucose cotransporter-2 (SGLT2) inhibitors and GLP-1 receptor agonists (GLP-1 RAs) reduce adverse cardiovascular outcomes in

GLP-1 Receptor Agonist Therapy with and without SGLT2 Inhibitors in Patients with Type 2 Diabetes Read More »

Supplementation with Cod Protein Hydrolysate in Older Adults: a Dose Range Cross-over Study

general /

The overall objective of the present study was to evaluate the effect of increasing doses of a supplement with CPH on glucose metabolism in older adults, aiming to find a dose response and creating a basis for an optimal daily dose for future clinical use. We investigated the effect on postprandial glucose regulation of four

Supplementation with Cod Protein Hydrolysate in Older Adults: a Dose Range Cross-over Study Read More »